Device Trial Radar · NCT02970799
Tear Production by Nasal Neurostimulation Compared to Active Control
Last checked: Nov 19, 2026Latest source record: Oct 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Aug 31, 2016
Primary completion
Oct 31, 2016
Study completion Oct 31, 2016
Sponsor
- Lead sponsor
- Oculeve, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 22, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This crossover design study evaluates the effectiveness of the Oculeve Intranasal Neurostimulator comparing the effect of intranasal (active) versus extranasal (control) stimulation on tear production as measured by the Jones Schirmer test in participants with dry eye disease.
Conditions
- Dry Eye
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
Interventions
Intranasal NeurostimulatorDevice
The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acute Tear Production by Jones Schirmer TestTime frame: Day 1
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.